180 related articles for article (PubMed ID: 35032639)
21. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
[TBL] [Abstract][Full Text] [Related]
22. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus.
Au Eong JTW; Lateef A; Liang S; Lim SHH; Tay SH; Mak A; Cho J
Rheumatology (Oxford); 2022 May; 61(5):1911-1918. PubMed ID: 34554232
[TBL] [Abstract][Full Text] [Related]
23. Blood Composite Scores in Patients with Systemic Lupus Erythematosus.
Mercader-Salvans J; García-González M; Quevedo-Abeledo JC; Quevedo-Rodríguez A; Romo-Cordero A; Ojeda-Bruno S; Gómez-Bernal F; López-Mejías R; Martín-González C; González-Gay MÁ; Ferraz-Amaro I
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893155
[TBL] [Abstract][Full Text] [Related]
24. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in pregnant women with systemic lupus erythematosus.
Ekici H; Imamoglu M; Okmen F; Gencosman G; Ak G; Ergenoglu M
J Obstet Gynaecol; 2022 Jul; 42(5):872-876. PubMed ID: 34565265
[TBL] [Abstract][Full Text] [Related]
26. The relationship of neutrophil-to-lymphocyte ratio with health-related quality of life, depression, and disease activity in SLE: a cross-sectional study.
Papachristodoulou E; Kakoullis L; Christophi C; Psarelis S; Hajiroussos V; Parperis K
Rheumatol Int; 2023 Oct; 43(10):1841-1848. PubMed ID: 37405441
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of the hemogram as a measure of clinical and serological activity in systemic lupus erythematosus.
Moreno-Torres V; Castejón R; Mellor-Pita S; Tutor-Ureta P; Durán-Del Campo P; Martínez-Urbistondo M; Vázquez-Comendador J; Gutierrez-Rojas Á; Rosado S; Vargas-Nuñez JA
J Transl Autoimmun; 2022; 5():100157. PubMed ID: 35620179
[TBL] [Abstract][Full Text] [Related]
28. Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?
Ozdemir A; Baran E; Kutu M; Celik S; Yılmaz M
Int Urol Nephrol; 2023 Jan; 55(1):211-216. PubMed ID: 35918626
[TBL] [Abstract][Full Text] [Related]
29. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
[TBL] [Abstract][Full Text] [Related]
30. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life.
Lai NS; Lu MC; Chang HH; Lo HC; Hsu CW; Huang KY; Tung CH; Hsu BB; Wu CH; Koo M
J Clin Med; 2021 May; 10(10):. PubMed ID: 34063379
[TBL] [Abstract][Full Text] [Related]
31. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
32. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study.
Wang CL; Koo M; Hsu CW; Lu MC
Lupus; 2023 Jun; 32(7):864-872. PubMed ID: 37165549
[TBL] [Abstract][Full Text] [Related]
33. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
34. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
[TBL] [Abstract][Full Text] [Related]
35. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
36. Correlation between the Modified Systemic Lupus Erythematosus Disease Activity Index 2000 and the European Consensus Lupus Activity Measurement in juvenile systemic lupus erythematosus.
Sato JO; Corrente JE; Saad-Magalhães C
Lupus; 2016 Nov; 25(13):1479-1484. PubMed ID: 27230556
[TBL] [Abstract][Full Text] [Related]
37. Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus.
Riaz MM; Shen L; Lateef A; Cho J
Lupus; 2022 Aug; 31(9):1121-1126. PubMed ID: 35676227
[TBL] [Abstract][Full Text] [Related]
38. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
39. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Ugarte-Gil MF; Acevedo-Vásquez E; Alarcón GS; Pastor-Asurza CA; Alfaro-Lozano JL; Cucho-Venegas JM; Segami MI; Wojdyla D; Soriano ER; Drenkard C; Brenol JC; de Oliveira e Silva Montandon AC; Costallat LT; Massardo L; Molina-Restrepo JF; Guibert-Toledano M; Silveira LH; Amigo MC; Barile-Fabris LA; Chacón-Díaz R; Esteva-Spinetti MH; Pons-Estel GJ; McGwin G; Pons-Estel BA;
Ann Rheum Dis; 2015 Jun; 74(6):1019-23. PubMed ID: 24525909
[TBL] [Abstract][Full Text] [Related]
40. Low serum uromodulin levels and their association with lupus flares.
David BL; Ivan GJ; Emilio PE; Daniela MJ; Betsabe CH; Luisa VM; Selene FN; Guadalupe AEA; Miriam SA; Alfredo C; Arturo NC; Mercedes HD; German CE; Gonzalez-Lopez L
PLoS One; 2022; 17(10):e0276481. PubMed ID: 36301848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
